No standalone psychedelic access bill will receive a House floor vote before year-end 2026; all action stays inside NDAA/appropriations.

Any bill in the US House of Representatives that focuses specifically on expanding access to psychedelics as medicine won't make it to a full floor vote before the end of 2026. Instead, any progress on psychedelics in federal law will be tucked inside larger must-pass bills — like the defense budget (called the NDAA, the National Defense Authorization Act) or spending bills. Standalone bills on controversial topics rarely get scheduled in election-adjacent years because lawmakers don't want to be on the record without political cover.

Election-year caution keeps members from standalone votes. Vehicles with cover survive; exposed bills don't get scheduled.